9,062 Shares in Illumina, Inc. $ILMN Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,062 shares of the life sciences company’s stock, valued at approximately $861,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ILMN. Empowered Funds LLC lifted its stake in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Illumina during the 2nd quarter valued at $621,000. Farther Finance Advisors LLC grew its stake in shares of Illumina by 9.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 2,521 shares of the life sciences company’s stock worth $241,000 after acquiring an additional 225 shares during the period. Park Avenue Securities LLC grew its stake in shares of Illumina by 9.5% during the 2nd quarter. Park Avenue Securities LLC now owns 6,609 shares of the life sciences company’s stock worth $631,000 after acquiring an additional 571 shares during the period. Finally, GAMMA Investing LLC increased its holdings in Illumina by 199.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,465 shares of the life sciences company’s stock worth $235,000 after acquiring an additional 1,642 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, with a total value of $61,065.00. Following the acquisition, the director directly owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This represents a 4.16% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 2.60% of the company’s stock.

Illumina Stock Down 2.4%

Shares of NASDAQ:ILMN opened at $150.28 on Friday. The firm has a fifty day moving average price of $135.20 and a two-hundred day moving average price of $113.23. The company has a market cap of $22.96 billion, a price-to-earnings ratio of 33.70, a PEG ratio of 2.50 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. Illumina, Inc. has a one year low of $68.70 and a one year high of $155.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The firm’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ILMN shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Guggenheim raised their price objective on shares of Illumina from $114.00 to $144.00 and gave the stock a “buy” rating in a report on Monday, January 5th. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Stifel Nicolaus increased their target price on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Barclays raised their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $124.47.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.